Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 1/20 | 0.45 |
| ▸ | NHERF1 | O14745 | 5/20 | 0.44 |
| ▸ | PYGL | P06737 | 9/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | BCAT1 | P54687 | 3/20 | 0.40 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6747980 | 0.91 | KDM4E (0.45) | NHERF1PYGLMEN1KMT2ARXFP1 | |
| SCHEMBL5740701 | 0.83 | NHERF1 (0.51) | NHERF1PYGLMEN1KMT2ARXFP1 | |
| SCHEMBL4124790 | 0.83 | NHERF1 (0.46) | NHERF1PYGLMEN1KMT2ARXFP1 | |
| SCHEMBL5730690 | 0.83 | NHERF1 (0.53) | NHERF1PYGLMEN1KMT2ARXFP1 | |
| SCHEMBL5730390 | 0.82 | NHERF1 (0.50) | NHERF1PYGLMEN1KMT2ARXFP1 | |
| SCHEMBL5731399 | 0.81 | NHERF1 (0.51) | NHERF1PYGLMEN1KMT2ARXFP1 | |
| SCHEMBL5730964 | 0.81 | NHERF1 (0.53) | NHERF1PYGLMEN1KMT2ARXFP1 | |
| SCHEMBL4120568 | 0.81 | POLB (0.50) | NHERF1PYGLMEN1KMT2ARXFP1 | |
| SCHEMBL6752795 | 0.81 | NHERF1 (0.50) | NHERF1PYGLMEN1KMT2ARXFP1 | |
| SCHEMBL5745550 | 0.81 | NHERF1 (0.50) | NHERF1PYGLMEN1KMT2ARXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1633709-A1 | ANTI-DIABETIC AGENTS | Pfizer Products Inc. (US) | 2006-03-15 | — | — | EP | claimed |
| WO-2004096768-A1 | ANTI-DIABETIC AGENTS | PFIZER PRODUCTS INC. (US) | 2004-11-11 | — | — | WO | claimed |
| US-20040220229-A1 | insulin resistance; central nervous system disorders; vision defects; anticholesterol agents;antilipemic agents; antiischemic agents | PFIZER INC | 2004-11-04 | — | — | US | claimed |
| US-8519137-B2 | Heteroaryl amides useful as inhibitors of voltage-gated sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-08-27 | — | — | US | disclosed |
| US-20090099233-A1 | HETEROARYL AMIDES USEFUL AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-04-16 | — | — | US | disclosed |
| EP-1633709-A1 | ANTI-DIABETIC AGENTS | Pfizer Products Inc. (US) | 2006-03-15 | — | — | EP | disclosed |
| WO-2004096768-A1 | ANTI-DIABETIC AGENTS | PFIZER PRODUCTS INC. (US) | 2004-11-11 | — | — | WO | disclosed |
| US-20040220229-A1 | insulin resistance; central nervous system disorders; vision defects; anticholesterol agents;antilipemic agents; antiischemic agents | PFIZER INC | 2004-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099233-A1 | HETEROARYL AMIDES USEFUL AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | CACNA1B, SCN3A, SCN2A | F10 3685/4885NHERF1 72/4885PYGL 4324/4885 |
| US-20040220229-A1 | insulin resistance; central nervous system disorders; vision defects; anticholesterol agents;antilipemic agents; antiischemic agents | IRS1, INSR, GPR119 | F10 1638/4885NHERF1 427/4885PYGL 97/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.